Goldman Sachs
NVET

Goldman Sachs’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Goldman Sachs’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,578
Closed -$60K – 7506
2015
Q4 		$60K Hold
17,578
– – ﹤0.01% 6451
2015
Q3 		$64K Buy
17,578
+99
+0.6% +$451 ﹤0.01% 6693
2015
Q2 		$87K Sell
17,479
-1,900
-10% -$13.2K ﹤0.01% 6683
2015
Q1 		$156K Buy
+19,379
New +$183K ﹤0.01% 6182

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's NVET Position: Q1 2016 in Review

Goldman Sachs sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q1 2016, closing a stake of 17,578 shares — an estimated $60K sold.

Goldman Sachs first reported a position in NVET in Q1 2015 and held it in 4 quarters. The position peaked at $156K in Q1 2015. 18 funds tracked by Wall St. Rank hold NVET as of Q1 2016.

  • Goldman Sachs reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q1 2016 after selling out during the quarter.
  • Goldman Sachs sold 17,578 Nexvet Biopharma plc Ordinary Shares shares in Q1 2016, an estimated $60K.
  • Goldman Sachs first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 4 quarters.
  • Goldman Sachs's Nexvet Biopharma plc Ordinary Shares position peaked at $156K in Q1 2015.
  • 18 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q1 2016.

Based on Goldman Sachs's 13F filing for Q1 2016, filed 13 May 2016.